Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary
Lantheus Holdings, Inc. (NASDAQ:NASDAQ:LNTH) Q2 2022 Earnings Conference Call Aug 4, 2022 8:08 AM Company Participants Mark Kinarney - Senior Director, Investor Relations Mary Heino -.